Journal of Bacteriology and Infectious Diseases

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Editorial - Journal of Bacteriology and Infectious Diseases (2025) Volume 9, Issue 2

Antimicrobial Resistance in Pathogenic Bacteria: Global Threats and Emerging Solutions

Tim Mathews *

School of Biological Sciences, University of Edinburgh, Edinburgh, UK

*Corresponding Author:
Tim Mathews
School of Biological Sciences,
University of Edinburgh, Edinburgh, UK
E-mail: mathewst65@imm.uzh.ch

Received: 01-Jan-2025, Manuscript No. AABID-24-171175; Editor assigned: 03-Jan-2025, PreQC No. AABID-24-171175(PQ); Reviewed:16-Jan-2025, QC No. AABID-24-171175; Revised:18-Jan-2025, Manuscript No. AABID-24-171175(R); Published: 24-Jan-2025, DOI:10.35841/aabid-9.2.196

Citation: Mathews T. Antimicrobial resistance in pathogenic bacteria: Global threats and emerging solutions. J Bacteriol Infec Dis. 2025; 9(2):196

Visit for more related articles at Journal of Bacteriology and Infectious Diseases

Introduction

Antimicrobial resistance (AMR) in pathogenic bacteria has emerged as one of the most pressing global health challenges of the 21st century. Once hailed as miracle drugs, antibiotics are now losing their efficacy due to the rapid evolution and spread of resistant bacterial strains. This phenomenon threatens to undermine decades of medical progress, making routine surgeries, childbirth, and infectious disease treatment increasingly risky. Understanding the scope of the threat and exploring emerging solutions is critical to safeguarding public health worldwide. AMR occurs when bacteria evolve mechanisms to survive exposure to antibiotics that would normally kill them or inhibit their growth. This resistance can be intrinsic or acquired through mutations or horizontal gene transfer. The World Health Organization (WHO) warns that AMR could cause 10 million deaths annually by 2050 if left unchecked [1].

AMR is not confined to human health—it spans animals, agriculture, and the environment. The One Health approach advocates integrated action across sectors to address AMR holistically. This includes regulating antibiotic use in livestock, improving waste management, and enhancing biosecurity in farms. Pathogenic bacteria such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Mycobacterium tuberculosis have developed resistance to multiple antibiotics, including last-resort drugs like carbapenems and colistin. Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are particularly concerning, with treatment success rates plummeting and costs soaring.: In both human medicine and agriculture, antibiotics are often prescribed unnecessarily or used as growth promoters in livestock [2].

Inadequate hygiene and sanitation in healthcare settings facilitate the spread of resistant bacteria. Resistant strains can quickly cross borders, making AMR a transnational issue. Pharmaceutical waste and agricultural runoff introduce antibiotics into soil and water, creating hotspots for resistance development. Efforts to combat AMR have gained momentum through international collaborations. The Global Antimicrobial Resistance Surveillance System (GLASS) launched by WHO aims to standardize data collection and monitor resistance trends worldwide. Regional initiatives like the European Antimicrobial Resistance Surveillance Network (EARS-Net) and India's National Programme on AMR Containment are also pivotal [3].

However, surveillance gaps persist in low- and middle-income countries due to limited laboratory capacity and funding. Strengthening global surveillance is essential for early detection and coordinated response. The development of new antibiotics is crucial, but progress has been slow due to scientific and economic hurdles. Recent breakthroughs include the discovery of teixobactin, a compound effective against gram-positive bacteria without detectable resistance. Drug repurposing and combination therapies are also being explored to enhance efficacy and delay resistance [4].

Bacteriophages—viruses that infect bacteria—are being revisited as alternatives to antibiotics. Phage therapy offers specificity and adaptability, making it suitable for targeting resistant strains. Clinical trials and compassionate use cases have shown promising results, especially in treating chronic infections. Stewardship programs promote the rational use of antibiotics through guidelines, education, and monitoring. Hospitals implementing stewardship have reported reduced antibiotic consumption and lower resistance rates. Public awareness campaigns are equally vital to curb self-medication and demand for unnecessary prescriptions. Timely identification of pathogens and their resistance profiles enables targeted treatment and reduces empirical antibiotic use. Advances in molecular diagnostics, such as PCR-based assays and next-generation sequencing, are revolutionizing clinical microbiology. Vaccines reduce the incidence of bacterial infections, thereby lowering antibiotic use and resistance pressure. For example, pneumococcal and typhoid vaccines have significantly reduced disease burden and antibiotic demand in endemic regions [5].

Conclusion

Antimicrobial resistance in pathogenic bacteria is a multifaceted global threat requiring urgent and coordinated action. While the challenges are formidable, emerging solutions—from novel therapies to integrated surveillance—offer a path forward. Success will depend on sustained investment, political will, and public engagement. In the battle against AMR, every stakeholder—from scientists and policymakers to patients and farmers—has a role to play. Governments and organizations are introducing policies to incentivize antibiotic development and stewardship. The AMR Action Fund, backed by pharmaceutical companies and global health institutions, aims to bring new antibiotics to market by 2030. Economic models like "delinkage" propose rewarding innovation without relying on sales volume, ensuring sustainable access.

References

  1. Blaustein R. The great oxidation event: evolving understandings of how oxygenic life on Earth began. BioScience. 2016;66(3):189-95.

    2. Google Scholar

  2. Philipp EE, Abele D. Masters of longevity: lessons from long-lived bivalves–a mini-review. Gerontology. 2010;56(1):55-65.

    3. Indexed at, Google Scholar, Cross Ref

  3. Imlay JA. The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium. Nat Rev Microbiol. 2013;11(7):443-54.

    4. Indexed at, Google Scholar, Cross Ref

  4. Baerlocher F. The Gaia hypothesis: a fruitful fallacy?. Experientia. 1990;46:232-8.

    5. Google Scholar

  5. Holliday J, Cleaver MP. Medicinal value of the caterpillar fungi species of the genus Cordyceps (Fr.) Link (Ascomycetes). A review. Int J Med Mushroom. 2008;10(3).

    6. Google Scholar

Get the App